ZNF300 and myelodysplastic syndrome: Taken all the results together, it is inferred that ZNF300 may act as a potential therapeutic target in MDS and AML against disease progression, and using ZNF300-based targeted therapy could improve the clinical outcome for MDS and AML patients.